கிறிஸ்டின் டிரான் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
There Is Enough Food, Just Not Enough Food Access
yesmagazine.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yesmagazine.org Daily Mail and Mail on Sunday newspapers.
Class action work has rarely been so dynamic
lawyersweekly.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lawyersweekly.com.au Daily Mail and Mail on Sunday newspapers.
Highlander Post Views: 130
My first frame of reference of college journalism was “Gilmore Girls.” I imagined myself zipping around a newsroom the same way Rory did, calling out pitches and writing interesting stories about campus. Less than a month after I arrived at UCR, I put my fantasy in motion by marching into The Highlander newspaper office. Even during my first few months as a writer, the paper managed to incite in me a flurry of emotions: nervousness, excitement, annoyance (ever write a great paragraph only for it to get cut?), but most of all, fulfillment. It was thrilling to create something every week and see it come to life in print. I knew I wanted to stay involved while I was at UCR.
Enthusiasm for Once-Monthly Cabenuva Is High But There Are Questions, Too
The landmark U.S. Food and Drug Administration (FDA) approval of the first long-acting injectable HIV regimen, Cabenuva (cabotegravir/rilpivirine), in January burst open a new treatment door for many people living with HIV (PLWH). The approval signaled a move from daily pills to two shots in the butt one for cabotegravir and the other for rilpivirine once a month. You may be asking, though, will doctors now start switching PLWH en masse from pills to injections? The short answer is no. And not everyone will even want to make the switch, although clinicians who recently spoke with TheBody said that, at least for the people who’ve heard about Cabenuva, enthusiasm is high.
vimarsana © 2020. All Rights Reserved.